ImmunityBio receives FDA warning letter on Anktiva promotion

In a warning letter posted to its site, the FDA stated: “The Office of Prescription Drug Promotion of the U.S. Food and Drug Administration has reviewed the promotional communications, a direct-to-consumer broadcast advertisement submitted by ImmunityBio (IBRX), under cover of Form FDA 2253 and a DTC podcast titled, ‘Is the FDA BLOCKING Life Saving Cancer Treatments?’ regarding Anktiva… The FDA Bad Ad Program also received complaints regarding promotional communications for Anktiva. FDA has determined that the TV ad and podcast are false or misleading.”